Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Cost-effectiveness analysis of interferon beta-1b as treatment for patients with clinically isolated syndrome suggestive of multiple sclerosis in Spain.
Antiinflammatory effects of orientin-2″-o-galactopyranoside on lipopolysaccharide-stimulated microglia.
The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial.
A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo.
Receptos announces issuance of composition of matter patents covering proprietary lead product candidate RPC1063
Rituximab for refractory digital infarcts and ulcers in systemic sclerosis.
FDA Accepts Filing of BETACONNECT™* for Relapsing-Remitting Multiple Sclerosis Patients Taking BETASERON® (interferon beta-1b)
Peripheral B cell depletion and central proinflammatory cytokine reduction following repeated intrathecal administration of rituximab in progressive Multiple Sclerosis.
BRIEF-Health Canada approves Genzyme's Aubagio to treat relapsing remitting multiple sclerosis
Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects.
Receptos Completes Enrollment of RADIANCE Phase 3 Trial of Ozanimod in Relapsing Multiple Sclerosis
Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions.
Improved detection of cortical MS lesions with phase-sensitive inversion recovery MRI.
Cladribine
Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis.
Biogen Reports Another Tecfidera PML Case
Pattern of demyelination occurring during anti-TNF-α therapy: a French national survey.
Vitamin D and multiple sclerosis: epidemiology, immunology, and genetics.
Mechanical environment modulates biological properties of oligodendrocyte progenitor cells.
Pharmacogenetic study of long-term response to interferon-β treatment in multiple sclerosis.
Momenta Pharmaceuticals Announces FDA Approval of ANDA for Glatopa(TM) (glatiramer acetate injection), the First Substitutable Generic for COPAXONE(R) (glatiramer acetate injection) 20mg
Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial.
Glatiramer acetate-induced acute hepatotoxicity in an adolescent with MS.
Generic interferon-beta
Genmab Announces Ofatumumab Development Plans in RRMS and NMO

Pages